ES2236849T3 - Inhibidores de la proteasa de vih. - Google Patents

Inhibidores de la proteasa de vih.

Info

Publication number
ES2236849T3
ES2236849T3 ES98113006T ES98113006T ES2236849T3 ES 2236849 T3 ES2236849 T3 ES 2236849T3 ES 98113006 T ES98113006 T ES 98113006T ES 98113006 T ES98113006 T ES 98113006T ES 2236849 T3 ES2236849 T3 ES 2236849T3
Authority
ES
Spain
Prior art keywords
mmol
alkyl
compound
amino
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98113006T
Other languages
English (en)
Spanish (es)
Inventor
Bruce A. Dressman
James E. Fritz
Marlys Hammond
William J. Hornback
Stephen W. Kaldor
Vincent J. Kalish
John E. Munroe
Siegfried Heinz Reich
John H. Tatlock
Timothy A. Shepherd
Michael J. Rodriguez
Louis N. Jungheim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agouron Pharmaceuticals LLC
Original Assignee
Agouron Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals LLC filed Critical Agouron Pharmaceuticals LLC
Application granted granted Critical
Publication of ES2236849T3 publication Critical patent/ES2236849T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/62—Isoquinoline or hydrogenated isoquinoline ring systems
ES98113006T 1993-10-07 1994-10-07 Inhibidores de la proteasa de vih. Expired - Lifetime ES2236849T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US13369693A 1993-10-07 1993-10-07
US13354393A 1993-10-07 1993-10-07
US133543 1993-10-07
US133696 1993-10-07
US08/190,764 US5484926A (en) 1993-10-07 1994-02-02 HIV protease inhibitors
US190764 1994-02-02

Publications (1)

Publication Number Publication Date
ES2236849T3 true ES2236849T3 (es) 2005-07-16

Family

ID=27384442

Family Applications (3)

Application Number Title Priority Date Filing Date
ES94930609T Expired - Lifetime ES2181725T3 (es) 1993-10-07 1994-10-07 Inhibidores de hiv proteasa.
ES98113006T Expired - Lifetime ES2236849T3 (es) 1993-10-07 1994-10-07 Inhibidores de la proteasa de vih.
ES03011749T Expired - Lifetime ES2287387T3 (es) 1993-10-07 1994-10-07 Inhibidores de la proteasa de vih.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES94930609T Expired - Lifetime ES2181725T3 (es) 1993-10-07 1994-10-07 Inhibidores de hiv proteasa.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES03011749T Expired - Lifetime ES2287387T3 (es) 1993-10-07 1994-10-07 Inhibidores de la proteasa de vih.

Country Status (36)

Country Link
US (14) US5484926A (sk)
EP (3) EP0889036B1 (sk)
JP (2) JP2951724B2 (sk)
KR (1) KR100190517B1 (sk)
CN (2) CN1195737C (sk)
AP (1) AP600A (sk)
AT (3) ATE362918T1 (sk)
AU (1) AU694746B2 (sk)
BG (1) BG62567B1 (sk)
BR (1) BR9407782A (sk)
CA (2) CA2173328C (sk)
CZ (1) CZ290417B6 (sk)
DE (3) DE69431193T2 (sk)
DK (2) DK0722439T3 (sk)
EE (1) EE05399B1 (sk)
ES (3) ES2181725T3 (sk)
FI (1) FI114794B (sk)
GE (2) GEP20002209B (sk)
HK (3) HK1013650A1 (sk)
HU (2) HU227885B1 (sk)
MD (1) MD1507G2 (sk)
MY (1) MY138860A (sk)
NO (1) NO307050B1 (sk)
NZ (2) NZ275633A (sk)
OA (1) OA10718A (sk)
PL (1) PL185647B1 (sk)
PT (2) PT889036E (sk)
RO (1) RO119363B1 (sk)
RU (1) RU2139280C1 (sk)
SI (2) SI0722439T1 (sk)
SK (2) SK284115B6 (sk)
TJ (1) TJ339B (sk)
TW (1) TW432049B (sk)
UA (1) UA56984C2 (sk)
UY (1) UY23840A1 (sk)
WO (1) WO1995009843A1 (sk)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878728B1 (en) 1999-06-11 2005-04-12 Vertex Pharmaceutical Incorporated Inhibitors of aspartyl protease
US20040122000A1 (en) 1981-01-07 2004-06-24 Vertex Pharmaceuticals Incorporated. Inhibitors of aspartyl protease
USH1649H (en) * 1987-07-31 1997-05-06 Barrish; Joel C. HIV protease inhibitor combinations
US7141609B2 (en) 1992-08-25 2006-11-28 G.D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
ES2177868T3 (es) 1992-08-25 2002-12-16 Searle & Co Hidroxietilaminosulfonamidas de alfa- y beta-aminoacidos utiles como inhibidores de proteasas retroviricas.
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5514801A (en) * 1992-12-29 1996-05-07 Monsanto Company Cyclic sulfone containing retroviral protease inhibitors
IL110255A (en) * 1993-07-16 1998-12-06 Merck & Co Inc Creation and resolution of 2 tert-butylcarboxamidopiprazine
DK0746320T3 (da) * 1994-02-02 2001-02-19 Lilly Co Eli HIV-proteaseinhibitorer og mellemprodukter
US5461154A (en) * 1994-02-02 1995-10-24 Eli Lilly And Company Intermediate and process for making
US5480887A (en) * 1994-02-02 1996-01-02 Eli Lilly And Company Protease inhibitors
US20030207813A1 (en) * 1996-12-09 2003-11-06 G.D. Searle Retroviral protease inhibitor combinations
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
US5831117A (en) * 1995-01-20 1998-11-03 G. D. Searle & Co. Method of preparing retroviral protease inhibitor intermediates
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6121468A (en) * 1995-09-26 2000-09-19 Japan Tobacco Inc. Process for producing amide derivatives and intermediate compounds
PT983999E (pt) 1995-09-26 2005-05-31 Agouron Pharma Processo para a producao de derivados amida e dos seus intermediarios
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
MY126358A (en) * 1996-03-22 2006-09-29 Glaxo Group Ltd Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
CN1134748C (zh) * 1996-06-05 2004-01-14 世雅企业股份有限公司 图像处理装置，图像处理方法，和游戏机
US5705647A (en) * 1996-09-05 1998-01-06 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
UA67727C2 (uk) * 1996-09-05 2004-07-15 Агурон Фармасевтікелс, Інк. Проміжні сполуки для одержання інгібіторів віл-протеази і способи одержання інгібіторів віл-протеази
US5925759A (en) 1996-09-05 1999-07-20 Agouron Pharmaceuticals, Inc. Methods of making HIV-protease inhibitors and intermediates for making HIV-protease inhibitors
US5962725A (en) 1996-09-05 1999-10-05 Agouron Pharmaceuticals, Inc. Intermediate compounds useful for making HIV protease inhibitors such as nelfinavir
US6232333B1 (en) * 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
DE19704885C1 (de) * 1997-02-11 1998-06-10 Clariant Gmbh Verfahren zur Herstellung von 3-Hydroxy-2-methylbenzoesäure und 3-Acetoxy-2-methylbenzoesäure
HRP980112A2 (en) * 1997-03-13 1998-12-31 Agouron Pharma Hiv protease inhibitors
US6001851A (en) * 1997-03-13 1999-12-14 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
JP3467043B2 (ja) * 1997-04-10 2003-11-17 エフ・ホフマン−ラ ロシュ アーゲー ブチルチオ−イソキノリン及びそれの中間体を製造するための方法
US6130348A (en) 1997-04-10 2000-10-10 Hoffmann-La Roche Inc. Process for a phenylthiobutyl-isoquinoline and intermediates therefor
US6123694A (en) * 1997-05-09 2000-09-26 Paragon Trade Brands Disposable absorbent article with unitary leg gathers
DE19730602A1 (de) * 1997-07-17 1999-01-21 Clariant Gmbh 3-Acetoxy-2-methylbenzoesäurechlorid und ein Verfahren zu seiner Herstellung
US6084107A (en) * 1997-09-05 2000-07-04 Agouron Pharmaceuticals, Inc. Intermediates for making HIV-protease inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
IN188157B (sk) 1998-01-16 2002-08-24 Japan Tobacco Inc
US6124500A (en) * 1998-03-09 2000-09-26 Rohm And Haas Company Process for synthesizing benzoic acids
FR2776292B1 (fr) * 1998-03-20 2004-09-10 Oncopharm Cephalotaxanes porteurs de chaine laterale et leur procede de synthese
WO1999054297A1 (fr) * 1998-04-16 1999-10-28 Nagase & Company, Ltd. Procede de preparation de chloroalcools et de leurs intermediaires
PT1086076E (pt) 1998-06-19 2005-05-31 Vertex Pharma Inibidores de sulfonamida de aspartil protease
US6538006B1 (en) 1998-07-08 2003-03-25 Pharmacia Corporation Retroviral protease inhibitors
US6107511A (en) * 1998-07-29 2000-08-22 Kaneka Corporation Process for the purification or isolation of (2S,3R)-1-halo-2-hydroxy-3-(protected amino)4-phenylthiobutanes or optical antipodes thereof
US7115584B2 (en) * 1999-01-22 2006-10-03 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7635690B2 (en) * 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
TWI260322B (en) 1999-02-12 2006-08-21 Vertex Pharma Inhibitors of aspartyl protease
CN1377261A (zh) 1999-03-22 2002-10-30 免疫力药品有限公司 治疗免疫疾病
US6566560B2 (en) 1999-03-22 2003-05-20 Immugen Pharmaceuticals, Inc. Resorcinolic compounds
US6589962B1 (en) 1999-07-20 2003-07-08 Merck & Co., Inc. Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
AU6109500A (en) * 1999-07-20 2001-02-05 Merck & Co., Inc. Alpha-hydroxy-gamma-(((carbocyclic-or heterocyclic-substituted)amino)carbonyl)alkanamide derivatives and uses thereof
KR100339831B1 (ko) 1999-08-18 2002-06-07 김태성 신규의 에틸 아지리딘 유도체 및 그 제조방법
US6403799B1 (en) 1999-10-21 2002-06-11 Agouron Pharmaceuticals, Inc. Methods for the preparation of intermediates in the synthesis of HIV-protease inhibitors
WO2001038332A1 (en) 1999-11-24 2001-05-31 Merck & Co., Inc. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors
DE60038899D1 (de) 2000-01-19 2008-06-26 Abbott Lab Hiv-proteasehemmern
US6992081B2 (en) 2000-03-23 2006-01-31 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
ATE343562T1 (de) * 2000-03-23 2006-11-15 Elan Pharm Inc Verbindungen und verfahren zur behandlung der alzheimerschen krankheit
US6448245B1 (en) 2000-05-04 2002-09-10 The United States Of America As Represented By The Department Of Health And Human Services Methods of and compounds for inhibiting calpains
US20020198207A1 (en) * 2000-05-18 2002-12-26 Kath John Charles Novel Hexanoic acid derivatives
US6846813B2 (en) * 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
AU2001273094A1 (en) 2000-06-30 2002-01-14 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease
EP1666452A2 (en) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease
US20030096864A1 (en) * 2000-06-30 2003-05-22 Fang Lawrence Y. Compounds to treat alzheimer's disease
US7425537B2 (en) * 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
AU2002213429A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Antiviral methods and compounds
AU2001296402A1 (en) * 2000-09-28 2002-04-08 Immugen Pharmaceuticals, Inc. Methods and compounds for inhibiting eicosanoid metabolism and platelet aggregation
IT1318986B1 (it) * 2000-10-09 2003-09-19 Archimica S P A Ora Clariant L Procedimento per la preparazione di (s)-n-terbutil-1,2,3,4-tetraidroisochinolin-3-carbossiammide.
EP2479578A1 (en) * 2000-10-19 2012-07-25 Target Discovery, Inc. Mass defect labeling for the determination of oligomer sequences
JPWO2002064553A1 (ja) * 2001-02-14 2004-06-10 呉羽化学工業株式会社 ハロゲノアルコール誘導体の製造方法
HN2002000136A (es) 2001-06-11 2003-07-31 Basf Ag Inhibidores de la proteasa del virus hiv, compuestos que contienen a los mismos, sus usos farmaceuticos y los materiales para su sintesis
EP1401452A1 (en) 2001-06-27 2004-03-31 Elan Pharmaceuticals, Inc. Beta-hydroxyamine derivatives useful in the treatment of alzheimer's disease
US20070213407A1 (en) * 2001-06-29 2007-09-13 Elan Pharmaceuticals And Pharmacia & Upjohn Company Llc Compounds to treat Alzheimer's disease
US20030191121A1 (en) * 2001-08-09 2003-10-09 Miller Ross A. Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation
US20030068655A1 (en) * 2001-09-12 2003-04-10 Protiveris, Inc. Microcantilever apparatus and methods for detection of enzymes
US6696494B2 (en) 2001-10-22 2004-02-24 Enanta Pharmaceuticals, Inc. α-hydroxyarylbutanamine inhibitors of aspartyl protease
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US20040067216A1 (en) * 2002-02-22 2004-04-08 Karki Shyam B. Hiv protease inhibitors supported on cation exchange resins for oral administration
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
US20030232101A1 (en) * 2002-03-18 2003-12-18 Immugen Pharmaceuticals, Inc. Topical formulations of resorcinols and cannibinoids and methods of use
DE10212885A1 (de) * 2002-03-22 2003-10-02 Bayer Ag Verfahren zur Herstellung von 3-Hydroxy-2-methylbenzoesäure
DE10226219A1 (de) * 2002-06-13 2004-01-08 Bayer Ag Verfahren zur Herstellung von 3-Acyloxy-2-methylbenzoesäuren
EP1371626A3 (de) * 2002-06-13 2004-07-21 Bayer Chemicals AG Verfahren zur Herstellung von 3-Alkoxy-2-methylbenzoesäuren
CA2393720C (en) 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
EP1400527B1 (de) * 2002-08-21 2006-03-22 Lanxess Deutschland GmbH Chirale Diphosphorverbindungen und deren Übergangsmetallkomplexe
WO2004073611A2 (en) 2003-02-13 2004-09-02 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
CN1819993A (zh) * 2003-05-08 2006-08-16 美国辉瑞有限公司 用于合成hiv－蛋白酶抑制剂的中间体及其制备方法
US7495011B2 (en) 2003-07-15 2009-02-24 Arigen Pharmaceuticals, Inc. Anti-coronavirus drug
US7211588B2 (en) * 2003-07-25 2007-05-01 Zentaris Gmbh N-substituted indolyl-3-glyoxylamides, their use as medicaments and process for their preparation
US8025899B2 (en) * 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
TR201906416T4 (tr) 2004-07-27 2019-05-21 Gilead Sciences Inc Hiv inhibitörü bileşiklerin fosfonat analogları.
EP1814858B1 (en) * 2004-08-23 2015-03-18 Mylan Laboratories Limited Novel crystalline forms of nelfinavir mesylate
CA2602854C (en) 2005-04-01 2013-05-14 Wellstat Therapeutics Corporation Compounds for the treatment of metabolic disorders
ES2426345T3 (es) 2005-07-20 2013-10-22 Eli Lilly And Company Compuesto unidos en posición 1-amino
WO2007015807A1 (en) 2005-07-20 2007-02-08 Eli Lilly And Company Phenyl compounds
EP1976377A4 (en) 2006-01-25 2010-06-23 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS
EP1976510A4 (en) 2006-01-25 2010-06-09 Wellstat Therapeutics Corp COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER
CN101378740A (zh) 2006-02-02 2009-03-04 维尔斯达医疗公司 用于治疗代谢紊乱的化合物
JP4831410B2 (ja) * 2006-02-28 2011-12-07 東亞合成株式会社 抗ウイルス性ペプチドおよび抗ウイルス剤
JP4788958B2 (ja) * 2006-02-28 2011-10-05 東亞合成株式会社 抗ウイルス性ペプチドおよびその利用
WO2007109160A2 (en) * 2006-03-16 2007-09-27 Renovis, Inc. Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2008033466A2 (en) * 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions and methods for treatment of viral diseases
WO2008041087A1 (en) * 2006-10-06 2008-04-10 Aurobindo Pharma Limited An improved process for preparation of amorphous nelfinavir mesylate
EP2131865B1 (en) 2007-03-12 2014-12-17 Nektar Therapeutics Oligomer-protease inhibitor conjugates
AU2008270634B2 (en) * 2007-06-29 2014-01-16 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
NZ582086A (en) * 2007-06-29 2012-07-27 Gilead Sciences Inc Therapeutic compositions and the use thereof
WO2009036341A2 (en) * 2007-09-14 2009-03-19 The Regents Of The University Of Michigan Compositions and methods relating to hiv protease inhibition
US20100093811A1 (en) * 2007-09-25 2010-04-15 Coburn Craig A Hiv protease inhibitors
EP2262538B1 (en) * 2008-03-12 2014-12-10 Nektar Therapeutics Oligomer-amino acid conjugate
UA103894C2 (ru) 2008-03-13 2013-12-10 Уеллстат Терепьютикс Корпорейшн Соединения и способ для снижения уровня мочевой кислоты
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
PL2364314T3 (pl) 2008-12-09 2014-08-29 Gilead Sciences Inc Modulatory receptorów Toll-podobnych
CA2955957A1 (en) * 2008-12-11 2010-06-17 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
US8551973B2 (en) * 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
WO2010075549A2 (en) 2008-12-23 2010-07-01 Pharmasset, Inc. Nucleoside phosphoramidates
CN102325783A (zh) 2008-12-23 2012-01-18 法莫赛特股份有限公司 嘌呤核苷的合成
CA2762582A1 (en) 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. Hiv protease inhibitors
US20120108501A1 (en) 2009-06-12 2012-05-03 Nektar Therapeutics Protease Inhibitors
US10640457B2 (en) 2009-12-10 2020-05-05 The Trustees Of Columbia University In The City Of New York Histone acetyltransferase activators and uses thereof
ES2907862T3 (es) * 2009-12-10 2022-04-26 Univ Columbia Activadores de histona acetiltransferasa y usos de los mismos
DE102010004957A1 (de) 2010-01-14 2011-07-21 Universitätsklinikum Jena, 07743 Biologisch wirksame Moleküle zur Beeinflussung von Virus-, Bakterien-, Parasiten-infizierten Zellen und/oder Tumorzellen und Verfahren zu deren Anwendung
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
SI3290428T1 (sl) 2010-03-31 2022-01-31 Gilead Pharmasset Llc Tableta, ki obsega kristalinični (S)-izopropil 2-(((S)-(((2R,3R,4R,5R) -5-(2,4-diokso-3,4-dihidropirimidin-1(2H)-il)-4-fluoro-3-hidroksi-4- metiltetrahidrofuran-2-il)metoksi)(fenoksi)fosforil)amino)propanoat
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
WO2012055031A1 (en) 2010-10-28 2012-05-03 Merck Canada Inc. Hiv protease inhibitors
EP2771332B1 (en) 2011-10-26 2016-06-29 Merck Canada Inc. Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS
CN104755475B (zh) 2012-09-11 2016-12-28 默沙东公司 Hiv蛋白酶抑制剂
WO2014068265A1 (en) 2012-10-29 2014-05-08 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
RU2505286C1 (ru) * 2012-12-29 2014-01-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
WO2015013835A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
RU2543322C1 (ru) * 2013-09-19 2015-02-27 Открытое Акционерное Общество "Фармасинтез" Фармацевтическая композиция для лечения вич-инфекции, способ ее получения и способ лечения
WO2015095265A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Hiv protease inhibitors
EP3082822B1 (en) 2013-12-19 2020-01-15 Merck Sharp & Dohme Corp. Hiv protease inhibitors
WO2015134366A1 (en) 2014-03-06 2015-09-11 Merck Sharp & Dohme Corp. Hiv protease inhibitors
US10138255B2 (en) 2014-03-10 2018-11-27 Merck Sharp & Dohme Corp. Piperazine derivatives as HIV protease inhibitors
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
KR102019572B1 (ko) 2014-07-11 2019-09-06 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 톨-유사 수용체의 조정제
WO2016069955A1 (en) 2014-10-29 2016-05-06 Wisconsin Alumni Research Foundation Boronic acid inhibitors of hiv protease
EP3349757A1 (en) 2015-09-15 2018-07-25 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of hiv
US10539397B2 (en) 2017-04-12 2020-01-21 Wilcox Industries Corp. Modular underwater torpedo system
EP3684767B1 (en) 2017-09-22 2024-04-24 Jubilant Epipad LLC Heterocyclic compounds as pad inhibitors
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
WO2019087214A1 (en) 2017-11-06 2019-05-09 Jubilant Biosys Limited Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
CN111542523B (zh) 2017-11-24 2024-03-29 朱比连特埃皮斯科瑞有限责任公司 作为prmt5抑制剂的杂环化合物
AU2019234185A1 (en) 2018-03-13 2020-10-01 Jubilant Prodel LLC. Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation
WO2021176369A1 (en) 2020-03-06 2021-09-10 Pfizer Inc. Methods of inhibiting sars-cov-2 replication and treating coronavirus disease 2019
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2448392A1 (fr) * 1979-02-12 1980-09-05 Vilbiss Toussaint De Dispositif automatique pour la projection de produits de revetement
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
IL91307A0 (en) * 1988-08-24 1990-03-19 Merck & Co Inc Hiv protease inhibitors and pharmaceutical compositions for the treatment of aids containing them
EP0361341A3 (en) * 1988-09-28 1991-07-03 Miles Inc. Therapeutics for aids based on inhibitors of hiv protease
US5063208A (en) * 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
WO1991008221A1 (en) * 1989-12-04 1991-06-13 Wisconsin Alumni Research Foundation Peptide inhibitors of hiv protease
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
CA2032259A1 (en) * 1989-12-18 1991-06-19 Wayne J. Thompson Hiv protease inhibitors useful for the treatment of aids
CA2056911C (en) * 1990-12-11 1998-09-22 Yuuichi Nagano Hiv protease inhibitors
RU2120447C1 (ru) * 1991-02-08 1998-10-20 Санкио Компани Лимитед ПРОИЗВОДНЫЕ β АМИНО α ГИДРОКСИКАРБОНОВЫХ КИСЛОТ ИЛИ ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫХ СОЛЕЙ ИЛИ ЭФИРОВ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ
US5235039A (en) * 1991-06-10 1993-08-10 Eli Lilly And Company Substrates for hiv protease
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
US5508407A (en) * 1991-07-10 1996-04-16 Eli Lilly And Company Retroviral protease inhibitors
US5220796A (en) 1991-07-15 1993-06-22 The Boc Group, Inc. Adsorption condensation solvent recovery system
DE4126482A1 (de) * 1991-08-10 1993-02-11 Bayer Ag (alpha)-trifluormethyl-substituierte, gesaettigt-bicyclische amine und verfahren zu deren herstellung
US5516784A (en) * 1991-08-13 1996-05-14 Schering Corporation Anti-HIV (AIDS) agents
EP0534511A1 (en) * 1991-08-16 1993-03-31 Merck & Co. Inc. HIV protease inhibitors useful for the treatment of aids
US5256783A (en) * 1991-09-18 1993-10-26 Hoffmann-La Roche Inc. Method for producing 2-isoquinoline compounds
WO1993008184A1 (en) * 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
AU3278293A (en) * 1991-12-20 1993-07-28 Syntex (U.S.A.) Inc. Cyclic amides of 3-amino-2-hydroxy-carboxylic acids as hiv-protease inhibitors
EP0560268B1 (en) * 1992-03-13 1995-01-04 Bio-Mega/Boehringer Ingelheim Research Inc. Substituted pipecolinic acid derivatives as HIV protease inhibitors
WO1993023379A1 (en) * 1992-05-21 1993-11-25 Monsanto Company Retroviral protease inhibitors
ES2177868T3 (es) * 1992-08-25 2002-12-16 Searle & Co Hidroxietilaminosulfonamidas de alfa- y beta-aminoacidos utiles como inhibidores de proteasas retroviricas.
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
MX9308025A (es) * 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
US5733906A (en) * 1993-10-12 1998-03-31 Eli Lilly And Company Inhibitors of HIV Protease useful for the treatment of Aids
US5475136A (en) * 1992-12-22 1995-12-12 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS
MX9308016A (es) 1992-12-22 1994-08-31 Lilly Co Eli Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
US5554653A (en) * 1992-12-22 1996-09-10 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5846993A (en) * 1992-12-22 1998-12-08 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
US5491166A (en) * 1992-12-22 1996-02-13 Eli Lilly And Company Inhibitors of HIV protease useful for the treatment of AIDS
US5434265A (en) * 1992-12-22 1995-07-18 Eli Lilly And Company Inhibitors of HIV protease
ES2150933T3 (es) 1992-12-22 2000-12-16 Lilly Co Eli Inhibidores de la proteasa vih utiles para el tratamiento del sida.
US5480887A (en) * 1994-02-02 1996-01-02 Eli Lilly And Company Protease inhibitors
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors

Also Published As

Publication number Publication date
US5827858A (en) 1998-10-27
DK0889036T3 (da) 2005-02-28
CN1262272A (zh) 2000-08-09
US20020077338A1 (en) 2002-06-20
BG100455A (en) 1997-09-30
CA2268709C (en) 2008-03-25
ES2287387T3 (es) 2007-12-16
HU0900219D0 (en) 2009-06-29
BR9407782A (pt) 1997-03-18
NO961382D0 (no) 1996-04-03
KR100190517B1 (en) 1999-06-01
JPH11310573A (ja) 1999-11-09
NO961382L (no) 1996-04-09
MD1507F2 (en) 2000-07-31
UY23840A1 (es) 1994-10-21
CN1131942A (zh) 1996-09-25
ES2181725T3 (es) 2003-03-01
DE69434214T2 (de) 2005-06-02
US6693199B2 (en) 2004-02-17
FI961449A0 (fi) 1996-03-29
SK284115B6 (sk) 2004-09-08
EP0722439B1 (en) 2002-08-14
PT722439E (pt) 2002-12-31
HK1056172A1 (en) 2004-02-06
DK0722439T3 (da) 2002-12-16
EP0722439A1 (en) 1996-07-24
US5827891A (en) 1998-10-27
NZ275633A (en) 1998-03-25
US5827859A (en) 1998-10-27
PT889036E (pt) 2005-05-31
US6162812A (en) 2000-12-19
DE69431193D1 (en) 2002-09-19
CA2173328C (en) 1999-08-31
HUT75652A (en) 1997-05-28
RO119363B1 (ro) 2004-08-30
HU9600908D0 (en) 1996-05-28
JP2951724B2 (ja) 1999-09-20
DE69434977D1 (de) 2007-07-05
CN1195737C (zh) 2005-04-06
US5834467A (en) 1998-11-10
AP600A (en) 1997-07-23
JPH09501443A (ja) 1997-02-10
CA2268709A1 (en) 1995-04-13
HU227885B1 (en) 2012-05-29
AU694746B2 (en) 1998-07-30
JP3703647B2 (ja) 2005-10-05
GEP20084497B (en) 2008-09-25
EE05399B1 (et) 2011-04-15
EP1340744A2 (en) 2003-09-03
AP9600844A0 (en) 1996-07-31
NZ329626A (en) 1999-08-30
SI0889036T1 (en) 2005-04-30
OA10718A (en) 2001-11-02
US6525215B2 (en) 2003-02-25
RU2139280C1 (ru) 1999-10-10
SK43996A3 (en) 1997-01-08
MY138860A (en) 2009-08-28
EP0889036A1 (en) 1999-01-07
US5852043A (en) 1998-12-22
GEP20002209B (en) 2000-08-25
HK1013650A1 (en) 1999-09-03
EP0889036B1 (en) 2004-12-29
PL185647B1 (pl) 2003-06-30
US20030216569A1 (en) 2003-11-20
WO1995009843A1 (en) 1995-04-13
DE69431193T2 (de) 2002-12-12
EP1340744B1 (en) 2007-05-23
UA56984C2 (uk) 2003-06-16
FI961449A (fi) 1996-05-29
US5859002A (en) 1999-01-12
SK284116B6 (sk) 2004-09-08
CZ100496A3 (en) 1996-09-11
DE69434977T2 (de) 2008-03-13
CA2173328A1 (en) 1995-04-13
HU226814B1 (en) 2009-11-30
ATE362918T1 (de) 2007-06-15
EE9600091A (et) 1996-12-16
CZ290417B6 (cs) 2002-07-17
AU7967494A (en) 1995-05-01
SI0722439T1 (en) 2002-10-31
ATE286025T1 (de) 2005-01-15
FI114794B (fi) 2004-12-31
ATE222240T1 (de) 2002-08-15
US5952343A (en) 1999-09-14
US5837710A (en) 1998-11-17
US6271235B1 (en) 2001-08-07
US5484926A (en) 1996-01-16
TJ339B (en) 2002-07-01
NO307050B1 (no) 2000-01-31
TW432049B (en) 2001-05-01
US5824688A (en) 1998-10-20
DE69434214D1 (de) 2005-02-03
BG62567B1 (bg) 2000-02-29
EP1340744A3 (en) 2003-12-03
HK1014950A1 (en) 1999-10-08
CN1046269C (zh) 1999-11-10
PL313871A1 (en) 1996-07-22
MD1507G2 (ro) 2001-04-30

Similar Documents

Publication Publication Date Title
ES2236849T3 (es) Inhibidores de la proteasa de vih.
EP0604182A2 (en) Inhibitors of HIV protease useful for the treatment of Aids
JPH06234728A (ja) Ａｉｄｓの処置のために有用なｈｉｖ−プロテアーゼ阻害剤
JPH06256277A (ja) Ａｉｄｓの処置のために有用なｈｉｖ−プロテアーゼ阻害剤
CA2112019A1 (en) Inhibitors of hiv protease useful for the treatment of aids
EP0970055A2 (en) Hiv protease inhibitors